Ubs Asset Management Americas Inc Celldex Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 102,595 shares of CLDX stock, worth $2.82 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
102,595
Previous 96,326
6.51%
Holding current value
$2.82 Million
Previous $3.57 Million
2.24%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$254 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$129 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$106 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$94.9 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$91.4 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.28B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...